Third-generation aromatase inhibitors extend treatment options far postmeno
pausal breast cancer patients refractory to initial antioestrogen therapy.
This article reviews advances and recent developments in hormonal therapy,
focusing in particular on exemestane, a new class of aromatase inactivator.